The GLP is committed to full transparency. Download and review our 2019 Annual Report

Why have mammograms failed to reduce breast cancer?

| | October 29, 2015

This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis. 

The whole idea behind cancer screening is that doctors will find the disease earlier — even before symptoms appear — and therefore be more likely to successfully treat it and control any spread.

But as the latest issue of the New England Journal of Medicine, shows, the introduction of mass mammography screening has failed to reduce the rate of advanced-stage breast cancers in women.

 

This isn’t the first time researchers have questioned the utility of population-wide mammography. Some medical associations and cancer societies have pushed back the initiation of mass screening, from about 40 years to 45 or 50 years. These general guidelines don’t apply to women who have a family history of the disease, or lifestyle factors and genetic markers that put them at a higher risk.

Read full, original post: How mass breast cancer screening failed to diagnose serious cases, in one chart

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend